SignPost Cancer Dx
Kingston
About SignPost Cancer Dx
SignPost Cancer Dx creates BreastDefense, a new class of precise diagnostic tests for breast cancer, based on molecular medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $250.0K
- Funding stage: Seed
- Last round: Seed (Jan 2023)
- Website: signpostcancerdx.com
- Phone: +1 613-532-1290
Industries & Categories
Health Care, Wellness
Canonical: https://fsome.com/organization/signpost-cancer-dx-157112 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.